Nonsurgical treatment of hepatocellular carcinoma

Seminars in Oncology

Volumn 28, Issue 5, 2001, Pages 503-513

  Aguayo, Alvaro ^a,b   Patt, Yehuda Z ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; INTERFERON; MITOXANTRONE; OCTREOTIDE; TAMOXIFEN; TEGAFUR; THALIDOMIDE;

ARTIFICIAL EMBOLISM; CANCER RADIOTHERAPY; CANCER SURVIVAL; CATHETER ABLATION; COMORBIDITY; CRYOSURGERY; DRUG EFFICACY; HUMAN; LIVER CELL CARCINOMA; NONSURGICAL INVASIVE THERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0034793993     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90143-5     Document Type: Article

References (119)

1. Epidemiological characteristics and risk factors of hepatocellular carcinoma
2. Rising incidence of hepatocellular carcinoma in the United States
3. Conditions associated with hepatocellular carcinoma
4. Hepatocellular carcinoma in Italian patients with cirrhosis
5. Risk factors for hepatocellular carcinoma among patients with chronic liver disease
6. Hepatocellular carcinoma
7. Hepatocellular carcinoma
8. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis
9. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: An 8-year prospective study by ultrasound and alphafetoprotein
10. Alcohol as a co-factor in the etiology of cancer
11. Alcohol and cancer
12. Alcohol and cancer
13. Hepatic resection versus transplantation for hepatocellular carcinoma
14. Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients
15. Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma
16. Radiofrequency ablation: An outpatient percutaneous treatment
17. Radiofrequecy ablation: A novel primary and adjunctive ablative technique for hepatic malignancies
18. The effects of hepatic cryosurgery on tumor growth in the liver
19. Cryosurgical ablation of hepatic tumors
20. Cryosurgery for unresectable primary hepatocellular carcinoma: A case report and review of literature
21. A collective review of the world literature on hepatic cryotherapy
22. Is cryosurgical ablation appropriate for treating hepatocellular cancer?
23. Ethanol injection for the treatment of hepatic tumours
24. Ablation of hepatocellular carcinoma by percutaneous ethanol injection: Imaging findings
25. Laparoscopic US-guided percutaneous ethanol ablation of hepatocellular carcinoma
26. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials
27. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients
28. Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy
29. Intraaterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: A clinical and pharmacology report
30. Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma
31. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis
32. Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study
33. Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison
34. Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump
35. Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies
36. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: Effects of hepatitis B and C viral infection on drug toxicity and patient survival
37. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma
38. Liver transplantation for hepatocellular carcinoma: Results with preoperative chemoembolization
39. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma
40. The treatment of hepatocellular carcinoma by chemoembolization
41. Hepatic arterial collaterals in Ivalon embolization of the hepatic artery
42. Effect of antimicrobial protection on tolerance to hepatic chemoembolization with a fibrous collagen carrier
43. Intra-arterial cis-platinum infusion with sodium thiosulfate protection and angiotensin II induced hypertension for treatment of hepatocellular carcinoma
44. A 5-year experience of lipiodolizadon: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma
45. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution
46. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma
47. Registries in Japan: Current status of hepatocellular carcinoma in Japan
48. Nonsurgical treatment of hepatocellular carcinoma in cirrhotic patients
49. Non-surgical treatment of hepatocellular carcinoma
50. Carcinoma of the liver
51. Iodine 131 antiferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group study
52. Selective internal radiation therapy with intra-arterial iodine-131-lipiodol in inoperable hepatocellular carcinoma
53. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol
54. 90Yttrium antiferritin - A new therapeutic radiolabeled antibody
55. Can current models explain the lack of liver complications in Y-90 microsphere therapy?
56. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy
57. Clinical evaluation of cryosurgery in the treatment of primary liver cancer. Report of 60 cases
58. Primary hepatocellular cancer - Present results and future prospects
59. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial
60. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with Adriamycin
61. 4'Epidoxorubicin (epirubicin): Activity in hepatocellular carcinoma
62. Gemcitabine, amifostine, and cisplatin (GAP) treatment for unresectable hepatocellular carcinoma (HCC)
63. A multicenter, phase II trial of gemcitabine and cisplatin in unresectable hepatocellular carcinoma
64. Diamminodichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma
65. Phase II studies of mitoxantrone in patients with primary liver cancer
66. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - A prospective randomized study of hepatitis C virus-related liver cancer
67. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C
68. Interferons in the management of viral hepatitis
69. A prospective phase II trial to evaluate the efficacy and toxicity of hepatic arterial infusion of ifosfamide in patients with inoperable localized hepatocellular carcinoma
70. Phase II study of high-dose ifosfamide in hepatocellular carcinoma
71. Phase II study of ifosfamide (Holoxan) in hepatoma
72. Current status of pyrazoloacridine as an anticancer agent
73. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis
74. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study
75. Continuous I.V. Infusion of 5-FU and subcutaneous recombinant interferon alpha 2b is an active regimen in fibrolamelar hepatocellular carcinoma
76. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: A communication
77. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
78. A phase II trial of tamoxifen in hepatocellular carcinoma
79. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma
80. Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial. Cancer of the Liver Italian Programme
81. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma
82. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma
83. Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma
84. Tamoxifen and radiotherapy in advance unresectable hepatocellular carcinoma
85. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma
86. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b
87. Continuous IV 5-flourouracil and subcutaneous recombinant interferon alpha 2b is an active regimen in hepatocellular carcinoma
88. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues
89. Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallblader cancer)
90. Scientific basis for the combination of tegafur with uracil
91. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin
92. UFT: East meets West in drug development
93. Phase II study of UFT plus leucovorin in colorectal cancer
94. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma
95. Angiogenesis
96. Angiogenesis in cancer, vascular, rheumatoid and other disease
97. Role of soluble mediators in angiogenesis
98. Basic fibroblast growth factor induces angiogenesis in vitro
99. Vascular endothelial growth factor is a secreted angiogenic mitogen
100. Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma
101. Prognostic value of angiogenesis in gastrointestinal turnouts
102. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver
103. Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the Vicenza studies
104. Tumor angiogenesis in advanced stage ovarian carcinoma
105. Vascular changes in hepatocellular carcinoma: Correlation of radiologic and pathologic findings
106. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study
107. The angiogenesis inhibitor TNP-470 (AGM-1470) improves long-term survival of rats with liver metastasis
108. Angiogenesis: An update
109. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
110. Tumor angiogenesis: Therapeutic implications
111. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats
112. Phase II trial of thalomid (thalidomide) for treatment of non-resectable hepatocellular carcinoma
113. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide
114. Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study
115. Regulatory peptide receptors in human hepatocellular carcinomas
116. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
117. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
118. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
119. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma